MCP To Produce Lyophilized Biologic for International Late-Phase Clinical Trials

MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials

PARSIPPANY, NJ September 19, 2012 — MCP Pharmaceuticals, a provider of global contract manufacturing services for sterile products has entered into an agreement with an undisclosed pharmaceutical company to produce supplies of a lyophilized biologic for international, late-phase clinical trials. Stuart Hinchen president and CEO of MCP stated, “We know that customers want to seamlessly progress from clinical batch production to product launch and then commercialization.

MCP’s established infrastructure and expertise transitioning products from clinical to commercial supply are recognized by customers looking for long- term reliability and continuity when selecting a contract manufacturing organization. Additionally, our cGMP compliance record and experienced staff allows customers to focus on their pressing business needs with confidence.” MCP has successfully supported launches of several products in US and international markets and manufactures products for sale in 86 countries. MCP’s Rochester, Michigan manufacturing site’s 25-year history in contract manufacturing is a result of a solid cGMP compliance record, a quality-driven experienced staff and a customer- centric approach.

About MCP Pharmaceuticals, LLC

MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, a clinical filling line and four lyophilizers.

The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical through large-scale commercial products. MCP employs more than 370 staff in the USA in its manufacturing, product development, regulatory, sales and marketing and corporate areas. For more information, please visit jhppharma.com.

Additional Press Releases
04/17/13
MCP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials
Webpage | PDF Format
12/31/12
MCP Pharmaceuticals Acquired By Warburg Pincus
Webpage | PDF Format
09/19/12
MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials
Webpage | PDF Format
06/07/12
MCP Pharmaceuticals Launches Generic Division
Webpage | PDF Format
06/05/12
MCP Pharmaceuticals to Produce Clinical and Commercial Supply of an Innovative Injectable
Webpage | PDF Format
02/29/12
MCP Pharmaceuticals Adds Second Product To Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
10/18/11
MCP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid
Webpage | PDF Format
07/25/11
MCP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug
Webpage | PDF Format
07/06/11
MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug
Webpage | PDF Format
07/05/11
MCP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
Webpage | PDF Format
06/24/11
MCP Pharmaceuticals Announces Chief Executive Officer Succession
Webpage | PDF Format
03/28/11
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
02/24/11
MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
01/27/11
MCP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
06/29/10
MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format
05/10/10
MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits
Webpage | PDF Format
09/28/09
MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
Webpage | PDF Format
08/20/08
MCP Pharmaceuticals & SpePharm complete purchaseof Dantrium® (dantrolene sodium)
Webpage | PDF Format
07/16/07
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP Pharmaceuticals
Webpage | PDF Format

Return To Press Releases »